Antihypertensive therapy leading to regression of left ventricular hypertrophy significantly improved midwall fractional shortening from 18.7% at baseline to 21.9% (P<0.05).
Observational (n=76)
Does antihypertensive therapy causing regression of LVH improve midwall myocardial shortening in hypertensive patients?
Regression of left ventricular hypertrophy through tight blood pressure control normalizes depressed midwall myocardial shortening in hypertensive patients.
Absolute Event Rate: 21.9% vs 18.7%
p-value: p=<0.05
Despite normal indices of left ventricular (LV) chamber function, patients with LV hypertrophy (LVH) due to hypertension are thought to have depressed midwall systolic shortening compared with normotensives. The aims of the present study were (1) to confirm this observation and (2) to assess the effects of antihypertensive therapy that cause regression of LVH on LV systolic function assessed at both the midwall and endocardium. Thirty-eight previously untreated hypertensive subjects with LVH underwent echocardiography and were compared with 38 normotensive control subjects. Comparisons between the group with LVH and the control group revealed no significant differences in cardiac output (4. 32+/-0.23 versus 4.55+/-0.21 L/min), ejection fraction (62.5+/-2% versus 66.4+/-1.07%), or endocardial fractional shortening (34.5+/-1.45% versus 37.0+/-0.82%), but shortening assessed at the midwall was significantly less in the group with LVH (17.9+/-1.11% versus 21.6+/-0.63%, P<0.01). Subsequently, 32 patients with uncontrolled hypertension (24 previously untreated and 8 on existing antihypertensive therapy) underwent treatment with ramipril, with the addition of felodipine and bendrofluazide if required, to reduce blood pressure to <140/90 mm Hg. These 32 patients underwent echocardiography at baseline, after blood pressure control, and after an additional 6 months of tight blood pressure control. Good blood pressure control was achieved after 6 months compared with baseline (143/86+/-2.8/1.4 versus 174/103+/-4.1/1.9 mm Hg; P<0.01) with significant regression of LV mass index (124+/-3.4 versus 145+/-3.8 g/m(2), P<0.01). LV fractional shortening assessed at the midwall improved with regression of LVH (21.9+/-0.84 and 18.7+/-1. 19%, P<0.05), with posttreatment midwall shortening being similar to that of the normal control subjects evaluated in the first study. Hypertensive patients with LVH have depressed midwall systolic shortening despite normal indices of LV chamber function. Regression of LVH after good blood pressure control improved midwall shortening to normal levels.
Mayet et al. (Wed,) conducted a observational in Hypertension with left ventricular hypertrophy (n=76). Ramipril, with felodipine and bendrofluazide if required vs. Baseline (pre-treatment) was evaluated on Midwall fractional shortening (p=<0.05). Antihypertensive therapy leading to regression of left ventricular hypertrophy significantly improved midwall fractional shortening from 18.7% at baseline to 21.9% (P<0.05).